Parmax Pharma Key Ratios

BSE: 540359

₹135.10

up-down-arrow ₹0.10 (0.07%)

As on 16-Nov-2026IST

Market cap

info icon

₹93 Cr

Revenue (TTM)

info icon

₹28 Cr

P/E Ratio

info icon

87.9

P/B Ratio

info icon

11.4

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 42.37 362.43 76.89 17.02 1.08
EBIT -630.09 -0.27 -24.39 -486.52 -207.10
Net Profit -92.18 108.28 127.53 54.40 -11.50
EPS -95.75 104.50 120.68 52.63 -12.86
Book Value -- -- -154.12 -213.02 -211.83
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info -29.05-16.25-13.66-38.41-2.76
Net Margin info -31.14-18.663.31-34.21-7.41
Return on equity info -92.48-55.27--0.000.00
Return on Capital info -55.44-31.15---76.70-29.88
Return on Assets info -21.96-13.153.80-18.60-12.36
Debt to Equity (x) info ----1.18-1.96-4.07
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
--
-76.70
-29.88
-59.76
3.96
Peer Median
--
23.14
30.15
25.60
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
--
--
--
-277.44
-2.26
Peer Median
19.26
18.10
22.45
20.46
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

3.80

Lower than Peers by 9.33

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
3.80
-18.60
-12.36
-34.91
-0.58
Peer Median
13.13
12.99
14.45
12.89
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-13.66

Lower than Peers by 31.27

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
-13.66
-38.41
-2.76
-45.97
2.46
Peer Median
17.61
18.02
14.69
13.67
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

3.31

Lower than Peers by 10.53

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
3.31
-34.21
-7.41
-51.80
-0.67
Peer Median
13.84
15.63
10.45
10.62
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
--
-25.97
-3.77
-36.54
11.50
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

76.89

Higher than Peers by 71.68

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
76.89
-57.06
155.17
-28.23
-15.57
Peer Median
5.20
16.83
6.12
2.92
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-24.39

Lower than Peers by 36.79

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
-24.39
-498.76
84.71
-1,438.89
-39.45
Peer Median
12.40
19.84
-1.86
24.62
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

127.53

Higher than Peers by 109.60

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
127.53
-98.62
63.59
-5,425.72
-173.54
Peer Median
17.93
24.00
1.68
29.22
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

120.68

Higher than Peers by 108.21

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
120.68
-98.62
63.59
-5,424.95
-173.56
Peer Median
12.47
23.21
-4.71
32.56
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
--
-154.12
-346.40
-112.73
6.55
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

1.18

Higher than Peers by 1.18

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
1.18
-1.96
-4.07
56.07
0.98
Peer Median
0.00
0.11
0.05
0.06
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.41

Lower than Peers by 0.78

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
1.41
0.74
0.69
0.63
1.06
Peer Median
2.19
2.09
2.06
1.89
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.13

Lower than Peers by 0.41

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
1.13
0.39
0.43
0.37
0.45
Peer Median
1.54
1.48
1.76
1.37
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

0.49

Lower than Peers by 24.45

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
0.49
-3.71
-3.09
-8.08
1.12
Peer Median
24.94
26.85
36.81
37.17
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

41.75

Higher than Peers by 27.61

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
41.75
26.11
4.53
16.43
4.04
Peer Median
14.14
17.31
13.72
13.52
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.99

Lower than Peers by 0.06

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
0.99
0.54
1.66
0.67
0.87
Peer Median
1.05
1.07
1.12
1.27
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
--
66.89
20.01
40.27
15.38
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
--
168.22
36.94
110.64
84.70
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
--
453.49
149.20
311.96
338.42
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
--
-218.39
-92.25
-161.05
-238.34
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

87.92

Higher than Peers by 36.32

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
87.92
--
--
--
--
Peer Median
51.61
51.61
55.67
50.55
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

11.44

Higher than Peers by 3.15

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
11.44
-1.55
-5.86
-17.63
2.39
Peer Median
8.29
8.29
10.68
9.96
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
--
--
--
--
--
Peer Median
0.86
0.86
0.65
0.54
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

46.49

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
46.49
-6.14
80.88
-4.97
7.10
Peer Median
--
44.75
38.80
44.18
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

93

Lower than Peers by 53,945

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Parmax Pharma
93
11
16
11
11
Peer Median
54,038
54,038
65,716
53,574
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...